Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 899

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 6
Chunk 899
---
 the terms of the 2019 Plan is 2,367,737. The remaining number of shares available to grant at September 30, 2025 is 693,515.

The Company’s 2019 Plan allows options to be granted to directors, officers, employees and certain external consultants and advisers. Under the 2019 Plan, the option term is not to exceed 10 years and the exercise price of each option is determined by the independent members of the Board of Directors.

Options have been granted under the 2019 Plan allowing the holders to purchase common shares of the Company as follows:

			Number of Options

			Weighted Average Exercise Price

			Weighted Average Grant Date Fair Value

			Balance - September 30, 2023

			420,615

			$
			25.60

			$
			18.84

			Granted

			500

			4.10

			3.10

			Forfeited

			(2,401
			)

			15.00

			10.70

			Expired

			(35,674
			)

			33.18

			24.63

			Balance - September 30, 2024

			383,040

			$
			24.93

			$
			18.33

			Forfeited

			(196
			)

			4.10

			3.10

			Expired

			(4,805
			)

			44.18

			37.95

			Balance - September 30, 2025

			378,039

			$
			24.70

			$
			18.12

There were no options exercised during the years ended September 30, 2025 or September 30, 2024. The intrinsic value of options outstanding at September 30, 2025 was $0.00.

The weighted average contractual life remaining on the outstanding options at September 30, 2025 is 68 months.

The following table summarizes information about the options under the 2019 Plan outstanding and exercisable at September 30, 2025:

			Number of Options

			Exercisable at
			September 30, 2025 (#) 

			Range of Exercise Prices 

			Expiry Dates